NL
DE
Current HPV-DNA testing in population screening for cervical cancer might have had it best time. A new test originating from Radboudumc gives a decisive answer within four days.
Related news items
Radboudumc Investment Day keeps growing
11 October 2024Scientists, entrepreneurs and investors from the life sciences & health sector came together to exchange knowledge, network and talk about new collaborations.
read more
Third Radboudumc Investment Day again well-attended
16 October 2023On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.
read more
Take Off 2 funding from NWO for Predica Diagnostics
30 June 2023Predica Diagnostics just secured the Take Off 2 funding to accelerate development of their cervical (pre)cancer prediction test.
read more
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Meet Healthy Ideas, Healthy Returns
2 June 2023Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.
read more
Innovation by Predica Diagnostics BV improves cervical cancer screening
26 July 2022A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL).
read more